Core Insights - The company reported a revenue of 6.084 billion yuan for 2024, representing a year-on-year growth of 8.55% [1] - The net profit attributable to shareholders was 921 million yuan, with a year-on-year increase of 1.19% [1] - The company achieved a non-dedicated net profit of 860 million yuan, reflecting a year-on-year growth of 9.79% [1] Revenue Breakdown - The revenue from the life sciences segment was 2.841 billion yuan, growing by 13.75% year-on-year [1] - The industrial testing segment generated 1.204 billion yuan, with a year-on-year increase of 10.32% [1] - The consumer products segment achieved 988 million yuan, showing a slight growth of 0.88% year-on-year [1] - The trade assurance segment reported 764 million yuan, with a year-on-year growth of 9.19% [1] - The pharmaceutical and medical testing segment faced a decline, generating 287 million yuan, down 14.71% year-on-year [1] Profitability Metrics - The company's gross margin was 49.47%, reflecting a slight increase of 1.41 percentage points year-on-year [2] - The net profit margin was 15.33%, showing a slight decline of 1.21 percentage points year-on-year [2] - The gross margins for different segments were as follows: life sciences at 50.42%, industrial testing at 45.25%, consumer products at 43.53%, trade assurance at 71.21%, and pharmaceutical and medical services at 20.43% [2] Future Outlook - The company is expected to achieve revenues of 6.965 billion yuan, 8.124 billion yuan, and 9.22 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of approximately 14%, 17%, and 14% [3] - The net profit attributable to shareholders is projected to be 1.093 billion yuan, 1.275 billion yuan, and 1.479 billion yuan for the same years, with growth rates of about 19%, 17%, and 16% [3] - The company maintains a strong competitive advantage in traditional sectors and is expected to drive business growth through proactive innovation [3]

Investment Rating - The report maintains an "Accumulate" rating for the company [1][8] Core Views - The company has demonstrated steady revenue growth with a year-on-year increase in gross margin [1][7] - In 2024, the company achieved total operating revenue of 6.084 billion and net profit attributable to shareholders of 0.921 billion, representing year-on-year growth of 8.55% and 1.19% respectively [3][4] - The company is focusing on consolidating its advantages in traditional sectors while expanding into strategic areas such as life sciences, industrial testing, and consumer product testing [4][5] Summary by Sections Financial Performance - In 2024, the company reported total operating revenue of 60.84 billion and net profit attributable to shareholders of 9.21 billion, with a year-on-year growth of 8.55% and 1.19% respectively [3] - For Q1 2025, the company achieved total operating revenue of 12.87 billion and net profit of 1.36 billion, reflecting year-on-year growth of 7.96% and 2.75% respectively [3] Business Segments - The life sciences segment generated revenue of 28.41 billion, up 13.75% year-on-year, while the industrial testing segment saw revenue of 12.04 billion, increasing by 10.32% [4] - The consumer product testing segment reported a modest growth of 0.88%, with revenue reaching 9.88 billion [4] - The trade assurance segment achieved revenue of 7.64 billion, up 9.19%, while the medical and health services segment faced a decline of 14.71%, generating 2.87 billion [4] Strategic Initiatives - The company is actively pursuing strategic acquisitions to enhance its global presence, including the acquisition of NAIAS in Greece to strengthen its maritime services [4][5] - The company has also acquired a 51% stake in Changzhou Microtech, a leading third-party testing agency in the electronic materials and PCB industry, to boost its influence in this sector [5] Profitability and Forecast - The overall gross margin for 2024 was reported at 49.47%, an increase of 1.41 percentage points year-on-year [7] - The report forecasts operating revenues of 65.40 billion, 71.05 billion, and 78.34 billion for 2025, 2026, and 2027 respectively, with net profits of 10.34 billion, 11.81 billion, and 12.86 billion [6][8]

Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting it to outperform the benchmark index by over 20% in the next six months [4][20]. Core Views - The company demonstrated resilient operations and improved profitability, with 2024 revenue reaching 6.08 billion yuan, a year-on-year increase of 8.55% [9][10]. - The report highlights the company's strategic focus on sustainable growth and innovation, particularly in traditional sectors like life sciences and trade assurance, while also expanding into new markets such as environmental testing and PCB testing services [9][10]. Financial Performance Summary - In 2024, the company achieved revenue of 6.08 billion yuan, net profit attributable to shareholders of 921 million yuan, and a non-recurring net profit of 860 million yuan, reflecting year-on-year growth of 8.55%, 1.19%, and 9.79% respectively [9][10]. - For Q1 2025, the company reported revenue of 1.29 billion yuan, a net profit of 136 million yuan, and a non-recurring net profit of 125 million yuan, with year-on-year increases of 7.96%, 2.75%, and 11% respectively [9][10]. - The gross margin for 2024 was 49.47%, with a net margin of 15.33% and a non-recurring net margin of 14.14%, indicating a slight improvement in profitability metrics [9][10]. - The company’s expense management remains strong, with sales, management, R&D, and financial expenses as a percentage of revenue showing minor fluctuations [9][10]. Strategic Initiatives Summary - The company is actively pursuing strategic acquisitions to enhance its global presence, including the acquisition of a Greek laboratory to strengthen its position in the green energy sector [9][10]. - It is also focusing on diversifying its service offerings in the aerospace and semiconductor sectors, aiming to build a comprehensive testing and certification service capability [9][10]. - The report emphasizes the company's commitment to innovation and operational efficiency, which are expected to drive future revenue and margin growth [9][10].

证券代码：300012 证券简称：华测检测 公告编号：2025-026 华测检测认证集团股份有限公司 关于公司股份回购完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华测检测认证集团股份有限公司（以下简称"公司"）于 2024 年 7 月 2 日 召开第六届董事会第十六次会议审议通过了《关于回购公司股份方案的议案》， 公司计划使用自有资金以集中竞价方式回购公司股份，回购的公司股份用于员工 持股计划或股权激励。本次拟回购股份数量为 200 万股-300 万股，回购股份价格 不超过人民币 16.83 元/股，按照回购数量上限 300 万股和回购价格上限 16.83 元/ 股的条件下测算，预计回购金额不超过 5,049 万元，具体回购股份的数量以回购 结束时实际回购的股份数量为准。本次回购实施期限为自公司董事会审议通过本 次回购股份方案之日起不超过 12 个月。具体内容详见公司 2024 年 7 月 3 日、2024 年 7 月 5 日在巨潮资讯网（http://www.cninfo.com.cn）上披露的《关于回购公 司股份方案的公告》（公告 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the benchmark index within the next six months [9][15]. Core Insights - The company reported a revenue of 6.084 billion yuan for 2024, representing an 8.55% year-on-year growth, and a net profit attributable to shareholders of 921 million yuan, which is a 1.19% increase [3][11]. - The company is positioned as a leading third-party testing enterprise, with strong operational quality and growth resilience, expected to navigate through economic cycles effectively [7][9]. - The company is focusing on high-quality development and actively entering emerging sectors such as AI testing and low-altitude economy, while also enhancing its service capabilities for major clients [6]. Financial Performance Summary - In 2024, the company achieved a gross margin of 49.47%, an increase of 1.42 percentage points year-on-year, with the life sciences segment showing the highest gross margin growth [5]. - The company’s revenue projections for 2025 to 2027 are 6.698 billion, 7.408 billion, and 8.150 billion yuan, with respective growth rates of 10.08%, 10.61%, and 10.02% [11][12]. - The net profit attributable to shareholders is forecasted to be 1.058 billion, 1.197 billion, and 1.349 billion yuan for the years 2025 to 2027, with growth rates of 14.83%, 13.19%, and 12.70% respectively [11][12].

2024年年报、2025年一季报披露进入高峰期，上市公司的业绩、机构持仓均浮出水面。有着"聪明钱"之称的QFII（合格境外机构投资 者）持仓是投资者最为关注的焦点之一。QFII都在买啥，美国加征关税是否对QFII的持仓造成影响？ 20股获QFII持仓超1% 整体上来看，披露2024年年报以及2025年一季报的个股中，截至2025年一季度末，QFII期末持仓数量及持仓市值环比均有所提升，持仓 市值超过5亿元的有紫金矿业、中国西电、华测检测等，其中中国西电持仓数量大幅提升。 从2025年一季度末QFII的持仓比例来看，截至2025年4月20日，45股前十大流通股东均有QFII身影，其中20股获持仓超1%，星宸科技、 阳光乳业、华测检测等7股持仓超过3%。 华测检测前十大流通股东出现摩根士丹利国际股份有限公司以及The Goldman Sachs Group, Inc.等QFII的身影。与此同时，公司今年一季 度还获得陆股通的大幅加仓，截至2025年一季度末，陆股通为公司第一大流通股东，持仓比例超过18%。 对阳光乳业、华测检测而言，QFII可以说是他们的"耐心资本"，其中华测检测早在2015年就获得QFII持仓， ...

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company achieved a revenue of 6.08 billion in 2024, a year-on-year increase of 8.6%, and a net profit attributable to shareholders of 921 million, up 1.2% year-on-year [5][6] - The company is expected to continue its growth trajectory with projected net profits of 996 million, 1.08 billion, and 1.17 billion for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 8.2%, 8.8%, and 8.1% [4][5] Revenue and Profitability - The company reported a significant increase in Q4 non-recurring profit, growing by 53%, driven by improved operational efficiency and reduced expense ratios [1] - The life sciences segment generated revenue of 2.84 billion, a 14% increase, with a gross margin of 50.4%, up 2.5 percentage points year-on-year [2] - The industrial testing segment achieved revenue of 1.2 billion, a 10% increase, with a gross margin of 45.3%, up 1.7 percentage points [2] - The trade assurance segment reported revenue of 760 million, a 9% increase, with a gross margin of 71.2%, up 6.6 percentage points [2] - The consumer products testing segment had revenue of 990 million, a 0.9% increase, with a gross margin of 43.5%, down 1.2 percentage points [2] - The medical segment faced a decline, with revenue of 290 million, down 15%, and a gross margin of 20.4%, down 19 percentage points [2] Cash Flow and Capital Expenditure - The company maintained strong operating cash flow with a net inflow of 1.06 billion in 2024, consistent with the previous year, and a net cash inflow of 790 million in Q4 [3] - Capital expenditure for the year was 690 million, representing 11% of revenue, with a focus on traditional business and new project investments [3] Strategic Initiatives - The company is accelerating its AI technology applications, with 15 pilot projects initiated by the end of 2024, focusing on defect detection and intelligent scheduling [4] - The company is actively pursuing strategic acquisitions in emerging sectors, including 100% stakes in companies in Greece and Hong Kong, enhancing its international presence [4]

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company achieved a revenue of 6.08 billion in 2024, representing an 8.6% year-on-year growth, with a net profit attributable to shareholders of 921 million, up 1.2% year-on-year [5][6] - The company is focusing on digital transformation and AI technology applications, with 15 AI application pilot projects initiated by the end of 2024 [4] - The company is actively pursuing strategic acquisitions in emerging sectors, including 100% stakes in NAIAS in Greece and Dahu Asia Pacific in Hong Kong [4] Summary by Sections Financial Performance - In Q4, the company reported a significant increase in non-recurring profit, growing by 53%, driven by improved operational efficiency and reduced expense ratios [1] - The company’s revenue for 2024 was 60.8 billion, with a quarterly breakdown of 12 billion in Q1, 16 billion in Q2, 16 billion in Q3, and 17 billion in Q4 [1] - The overall gross margin for 2024 improved to 49.5%, a 1.4 percentage point increase year-on-year [2] Business Segments - Life Sciences segment revenue reached 2.84 billion, up 14%, with a gross margin of 50.4% [2] - Industrial Testing segment revenue was 1.2 billion, up 10%, with a gross margin of 45.3% [2] - Trade Assurance segment revenue was 760 million, up 9%, with a gross margin of 71.2% [2] - Consumer Products Testing segment revenue was 990 million, up 0.9%, with a gross margin of 43.5% [2] - Pharmaceutical segment revenue was 290 million, down 15%, with a gross margin of 20.4% [2] Cash Flow and Capital Expenditure - The company reported a net cash inflow of 1.06 billion from operating activities in 2024, maintaining a net cash ratio of 115% [3] - Capital expenditure for the year was 690 million, accounting for 11% of revenue, with a focus on traditional and new projects [3] Future Outlook - The company forecasts net profits of 996 million, 1.084 billion, and 1.171 billion for 2025, 2026, and 2027 respectively, with expected growth rates of 8.2%, 8.8%, and 8.1% [4][5]

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company's revenue growth is stable, with government subsidies and other non-operating factors impacting net profit. In 2024, the company achieved total revenue of 6.1 billion yuan, a year-on-year increase of 9%, and a net profit of 920 million yuan, a year-on-year increase of 1%. The non-recurring profit decreased by 0.65 million yuan due to reduced government subsidies [2] - The gross margin is steadily increasing, with significant results from lean management. In 2024, the company's gross margin was 49.5%, up 1.4 percentage points year-on-year, while the net profit margin was 15.3%, down 1.2 percentage points year-on-year [3] - The company is well-positioned for long-term growth due to its forward-looking, diversified layout, and international strategy. The company is expanding into new markets such as pet food and renewable energy, and enhancing its overseas presence through acquisitions [4] Revenue and Profit Forecast - The company forecasts total revenue of 6.1 billion yuan for 2024, with a net profit of 921 million yuan. The projected net profit for 2025 is adjusted to 1.06 billion yuan, with a corresponding P/E ratio of 18 [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 （二）内部控制环境 1、治理结构 公司按照《中华人民共和国公司法》、《中华人民共和国证券法》、《深圳证券交易所上市公司自律监 管指引第2号一一创业板上市公司规范运作》等法律、行政法规、部门规章的要求，建立了规范的公司 治理结构和科学的议事规则，制定了符合公司发展要求的各项制度和程序，明确决策、执行、监督等方 面的职责权限，形成了科学有效的职责分工和制衡机制。股东大会、董事会、监事会分别按其职责行使 决策权、执行权和监督权。股东大会享有法律法规和公司章程规定的合法权利，依法行使对公司经营方 针、筹资、投资、利润分配等重大事项的决定权。 董事会对股东大会负责，依法行使企业的经营决策权。董事会7名董事中，有3名独立董事。独立董事担 任审计委员会、薪酬考核与提名委员会专门委员会的召集人，专门委员会可对涉及专业领域的事项进行 事前审核，以利于独立董事更好地发挥作用。 每年集团总部财务对分、子公司财务进行会计基础工作检查，内审部对法人治理、廉洁文化建设、信息 安全、内部控制等情况进行检查监督。管理层根据董事会的授权，负责组织实施股东大会、董事会决议 事项，主持企业日常经营 ...